Bladder Cancer

Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer: comparison between patients from a Dutch nationwide cohort and KEYNOTE-045.

Pending adoption of enfortumab-vedotin plus pembrolizumab in first-line setting, platinum-based chemotherapy remains the standard of care for patients with metastatic or locally advanced urothelial cancer (mUC).

Challenges in Defining Clinical Complete Response to Systemic Therapy in Muscle-invasive Bladder Cancer: Insights from the EORTC STARBURST Project.

The standard of care (SOC) for treatment of muscle-invasive bladder cancer is neoadjuvant systemic treatment (NAT) with chemotherapy ± immunotherapy (pending durvalumab approval for this indication) followed by cystectomy or radiochemotherapy, regardless of the extent of any tumor response.

A pilot study of [18F]F-fluciclovine positron emission tomography/computed tomography for staging muscle invasive bladder cancer preceding radical cystectomy.

To assess the ability of [18F]F-fluciclovine-PET/CT to stage muscle invasive bladder cancer (MIBC) before radical cystectomy.

This single-site prospective pilot study enrolled patients with MIBC and T2-T4, N0 disease on CT/MRI slated to undergo radical cystectomy (RC).

Patient Versus Clinician Reported Symptoms Agreement in Advanced Metastatic Bladder Cancer Patients.

Immune checkpoint inhibitors (ICIs) improved survival in patients with locally advanced or metastatic urothelial carcinoma (la/mUC). Patient-reported symptoms in this context were poorly studied. The study aimed to compare symptom severity between patients and clinicians.

New insights and emerging approaches in bladder-sparing treatment for muscle-invasive bladder cancer.

Muscle-invasive bladder cancer (MIBC) poses significant challenges, traditionally treated with radical cystectomy, a procedure with considerable morbidity and impact on quality of life. Bladder-sparing approaches aim to preserve the bladder while maintaining oncological efficacy.

The Effect of Chronic Kidney Disease on Adverse In-Hospital Outcomes after Radical Cystectomy with Ileal Conduit Urinary Diversion - Beyond the Abstract

Our recent study investigated the impact of chronic kidney disease (CKD) on in-hospital outcomes in patients undergoing radical cystectomy (RC) with ileal conduit urinary diversion, using data retrieved from the NIS database (2006-2019).

A Systematic Review of Novel Intravesical Approaches for the Treatment of Patients with Non-muscle-invasive Bladder Cancer.

Intravesical therapy is central to managing non-muscle-invasive bladder cancer (NMIBC); yet, recurrence and progression remain common, underscoring the need for new treatments. This systematic review evaluates clinical trials of novel intravesical therapies for all risk categories of NMIBC.

Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance).

Cisplatin-based chemotherapy has been a cornerstone of therapy for advanced/metastatic urothelial cancer (mUC). However, no genomic characteristics have been validated as prognostic biomarkers for this therapy.

Long-Term Outcomes of Robot-Assisted Radical Cystectomy in Patients with Non-Muscle-Invasive Bladder Cancer - Expert Commentary

Radical cystectomy is an effective treatment option for high-risk, non-muscle-invasive bladder cancer (NMIBC) to prevent progression. A recent 12-year multicenter study evaluated survival outcomes of patients with NMIBC who underwent robot-assisted radical cystectomy (RARC) with intracorporeal urinary diversion (ICUD).

Treatment of Metastatic Urothelial Carcinoma in the United Kingdom, France, Germany, Italy, and Spain - Beyond the Abstract

Urothelial carcinoma (UC) is the most common form of bladder cancer, accounting for nearly 90% of cases globally.1 While earlier diagnoses have improved overall survival rates in recent years, the prognosis remains poor for patients progressing to metastatic disease, with 5-year average survival rates in Europe and the United States at or below 10%.1-4